Design Therapeutics, Inc.
DSGN
$5.41
$0.214.04%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -61.82% | -59.52% | -15.28% | 17.42% | 40.85% |
Total Depreciation and Amortization | 0.66% | 11.19% | 7.97% | 11.68% | 13.53% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 102.08% | 69.87% | 127.32% | 9.55% | -25.81% |
Change in Net Operating Assets | 173.74% | 41.79% | 181.13% | 519.25% | -136.75% |
Cash from Operations | -28.25% | -34.97% | 22.96% | 34.32% | 18.43% |
Capital Expenditure | 45.96% | 63.08% | 100.00% | 130.19% | -80.90% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -26.52% | -61.84% | -67.18% | -138.14% | 127.77% |
Cash from Investing | -26.40% | -61.83% | -67.02% | -138.16% | 128.12% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 57.64% | 15.00% | -47.50% | -92.31% | 9.05% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 57.64% | 15.00% | -47.50% | -92.31% | 9.05% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -62.97% | -208.53% | -15.17% | -2,163.22% | 1,111.29% |